Reckitt Benckiser Share Discussion Threads

[brain smiley] 12/2/2009 11:40

Liarspoker

Your a patronising git...lol. No wonder your ignored on here.

Thank for the reply.

Anyway, good luck.

[liarspoker] 12/2/2009 11:07

An aqcuisition would not enhance earnings immediately and if they do then probably not to the extend of the Soboxone loss. Anyway focusing immediately on earnings on a new acquisition is the wrong view to take. Best see how it fits in with the overall organisation and check past operating results.

Don't take too much note of boker notes. I like them because they often tell me something new about a companies operations but best to try to value a company yourself imo. You'll improve over time and your decisions will be your own then, they won't be dependent on broker ( or anyone elses ) forecasts. That's a better way to invest.

Well done on spotting the Suboxone issue btw. :O)

[brain smiley] 12/2/2009 11:00

Liarspoker

It's all very odd -broker upgrades when RB will lose around 10% of profits when suboxone goes in Sept 2009.

Maybe the brokers reckon RB can make more money on this drug in Europe and make an aquisition to partly offset the loss.

[liarspoker] 12/2/2009 09:53

brain smiley - whatever company you invest in always go to the investor relations page on their website and look through the presentation slides. The Suboxone info is there for everyone to see clearly.

There's a large tax payment due in SFR. I pointed that out on the thread but it was either commented that I was an idiot or not commented on at all. Strange. I think that 95% of ADVFN punters still believe in fairy tales. :O)

[brain smiley] 12/2/2009 09:50

Heres some broker chat from today:

*RBS says buy Reckitt Benckiser, lifts price target to £32 from £30.

Deutsche Bank has lifted its target on Reckitt Benckiser to £33 from £30

Societe Generale repeated its buy view on Reckitt Benckiser after strong numbers yesterday, ups price target to £31 from £30.

[brain smiley] 12/2/2009 09:27

Reckitt made nearly £1.2 billion in 2008 and then this...

"As a result of its Orphan Drug Status, Suboxone has exclusivity in
the USA until the end of September 2009 and in Europe until 2016. Within the
Pharmaceuticals division, the US Suboxone business generated FY net revenue of
£285m and adjusted operating profit of £172m. While the Group continues to
search for ways to offset the impact of the loss of exclusivity in the USA at
the end of September 2009, up to 80% of the revenues and profits of that
business might be lost to generic competition in 2010, with the possibility of
further erosion thereafter."

How are RB going to replace these profits. Some margin to make £172m from sales of £285m !!

Surely RB shares should be falling but the broker notes I see(barring investec) don't even mention this and are very bullish.

You would think the profit figures about Suboxone are wrong.

[paul w] 11/2/2009 23:07

see the FT-

While the figures were stronger than Unilever's, after stripping out pharmaceuticals the underlying fourth-quarter trend was similar: slowing core sales growth and margin compression.

[scburbs] 11/2/2009 19:46

Fair play to RB., an excellent set of results and a reasonable outlook. Medium term growth looks tricky though. In particular, this issue in relation to 15% of the group's 2008 operating profits.

"As a result of its Orphan Drug Status, Suboxone has exclusivity in
the USA until the end of September 2009 and in Europe until 2016. Within the
Pharmaceuticals division, the US Suboxone business generated FY net revenue of
£285m and adjusted operating profit of £172m. While the Group continues to
search for ways to offset the impact of the loss of exclusivity in the USA at
the end of September 2009, up to 80% of the revenues and profits of that
business might be lost to generic competition in 2010, with the possibility of
further erosion thereafter."

[huwrayhenry] 05/2/2009 21:18

big seller out there today?

[batman9] 25/12/2008 15:47

Merry Christmas to all on the RB. board.

[scburbs] 17/12/2008 23:04

I certainly can't disagree with you Brain Smiley, very sensible for him to sell some IMV!!

[brain smiley] 15/12/2008 11:02

scburbs

He has £33 million worth of RB shares - sensible to sell some off.

A director bought 30k worth last friday - better sign.

[scburbs] 14/12/2008 20:00

CEO raising multi-millions by selling shares is never good for confidence.

[brain smiley] 10/12/2008 10:12

Well done the shorters..

What's up with RB. ?

[huwrayhenry] 04/12/2008 12:20

yep, short these too.

[jas_ron] 03/12/2008 19:14

nice short late today at 28 squid me thinks

[jas_ron] 19/11/2008 19:32

yep me too scburbs - looking forward to a sharp drop.

[scburbs] 19/11/2008 12:33

RB less than 10% off record highs whilst the economy is on the floor. Either heavily undervalued when the economy was performing well or heavily overvalued now. No prizes for guessing which view I hold.

[bonzo1] 19/11/2008 11:09

upgraded today and will be shorting later me thinks.

[batman9] 14/11/2008 10:15

Elssworth - ING cuts Reckitt Benckiser price target to 3000P from 3100P; keeps buy rating.
Hope this helps.

[elssworth] 07/11/2008 20:23

The Prof is looking to add small batches of shorts in RB...Level 4 shorting alarm went off today, telling me to advise clients to keep this one on the tab.

For the record, Level 4 has a short term target of £13.27
Hope this helps

[scburbs] 28/10/2008 08:41

Rather a brief outlook statement! All investors would have been interested on any comments on the impact of the current macro economic situation. RB went for no comment and just looked at 1 quarter ahead.

Has anyone listened to the webcast on this point yet?

[cambium] 27/10/2008 12:32

Reckitt Benckiser Group PLC:
* Q3 adjusted net income 285 million pounds versus 218 million year ago
* Raising our full year target for net revenue growth to +13% from at least
+11-12%
* For net income growth, we are confident of achieving at least our
previously
communicated target of +11% at constant exchange

[indieman] 20/10/2008 06:36

scburbs,

I don't disagree with your prognosis. As I've said above, RB trades at a premium because of its perceived defensive status. A high p/e makes it vulnerable in irrational markets or a prolonged global downturn.

The high p/e depends on growth and it is the question of where that growth can come from which might show potential weaknesses.

In other words, reverting to my previous point, where people choose not to trade up to RB products, rather than where people choose to trade down from them.